{"entity":{"id":"julie-park","kind":"person","name":"Julie R. Park","aka":[],"tldr":"Julie Park led the COG trial that made tandem transplant standard for high-risk neuroblastoma.","summary":"Julie Park is Chair of the Department of Oncology at St. Jude Children's Research Hospital and a neuroblastoma investigator with the Children's Oncology Group (COG). A paediatric oncologist specialising in neuroblastoma and immunotherapy, she was study chair of COG ANBL0532, the randomised trial of tandem versus single autologous stem cell transplant in high-risk neuroblastoma that made tandem transplant standard, and is a leader in anti-GD2 immunotherapy studies linked to COG ANBL0032 and dinutuximab. Her papers report the tandem transplant trial in JAMA and the revised International Neuroblastoma Response Criteria consensus statement in the Journal of Clinical Oncology. Her work centres on GD2-directed therapy in paediatric neuroblastoma.","asOf":"2026-09-08","links":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20JR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Julie%20R.%20Park"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":["gd2"],"drugs":["dinutuximab"],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":["anbl0032","anbl0532"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Oncology, St. Jude Children's Research Hospital; Children's Oncology Group neuroblastoma investigator","institutionId":"childrens-oncology-group","specialisms":["Neuroblastoma","Immunotherapy","Paediatric oncology"],"profiles":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20JR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Julie%20R.%20Park"}],"papers":[{"title":"Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial","journal":"JAMA","year":2019,"url":"https://doi.org/10.1001/jama.2019.11642","doi":"10.1001/jama.2019.11642"},{"title":"Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting","journal":"Journal of Clinical Oncology","year":2017,"url":"https://doi.org/10.1200/JCO.2016.72.0177","doi":"10.1200/JCO.2016.72.0177"}],"orcid":"0000-0002-6777-9165"},"route":"/people/julie-park/","neighbours":{"cancer":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"target":[{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/"}],"drug":[{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/"}],"company":[{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/"}],"trial":[{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/"},{"id":"anbl0532","kind":"trial","name":"COG ANBL0532","route":"/trials/anbl0532/"}],"institution":[{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/"}]}}